As measured by the nine-item Quality of Life-Bronchiectasis Respiratory Domain (QOL-B RD), 43.8% of patients in the ALIS arm achieved a meaningful improvement in symptoms from baseline to 7 months, as compared with 33.3% of those assigned to the macrolide-based regimen plus placebo, reported Charles Daley, of National Jewish Health and the University of Colorado School of Medicine in Denver.
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045